The technology helps to solve the age-old problem of supplement bioavailability.
Response Scientific CEO Gregg Webster noted the reality is that some of the most promising dietary supplements are poorly bioavailable.
"Our Microvail™ protective microencapsulation technology could revolutionize the supplement and nutraceutical markets because it delivers a higher percentage of microparticle-formulated nutrients into the bloodstream based upon our internal testing," Webster added.
Response Scientific’s Microvail microencapsulation technology not only protects nutraceuticals from stomach acids and enzymes, but also features a unique means of time-release by using diffusion, rather than an enteric coating.
The microparticles pass through the capsule wall while in transit through the small intestine. The microcapsules continue to release their contents thus maximizing the bioavailability and absorption of microparticle-formulated nutrients into the bloodstream.
The Microvail name is derived from the combination of microencapsulated and bioavailable. Bioavailability refers to the amount of any drug or nutrient that enters the bloodstream at a high percentage rate or low percentage rate due to damage. Hence, a product that enters the bloodstream is said to be either highly bioavailable, or poorly bioavailable.
Microvail’s unique packaging is another industry first. Microvail micronutrients are packaged in single dose, easy-to-open, sealed foil pouches, making them highly portable and convenient. The capsules themselves are about the size of a grain of salt and easy to swallow with a minimal amount of liquid or saliva.
The Microvail ‘microencapsulated micronutrients’ will be branded under the Microvail trade name and sold exclusively to retail stores.
Response Scientific will continue to finalize investment rounds to support 2014 production and marketing development in preparation for the Canadian launch of Microvail.